Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
Home › Stocks › Frazier Lifesciences Acquisition Corporation (FLAC) Stock Forecast & Price Prediction United States | NASDAQ | |
$17.61
-0.67 (-3.67%)10 Quality Stocks Worth Considering Now
Researching Frazier Lifesciences (FLAC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on FLAC and similar high-potential opportunities.
FLAC has shown a year-to-date change of -32.2% and a 1-year change of -6.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for FLAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
These are the latest 20 analyst ratings and price targets for FLAC.
Date | Firm | Analyst | Rating | Change | Price Target |
---|
The following stocks are similar to Frazier Lifesciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Frazier Lifesciences Acquisition Corporation has a market capitalization of $251.84M with a P/E ratio of 65.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +3.2%.
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
0
United States
2021
Frazier Lifesciences Acquisition Corp. completed its business combination on November 22, 2022, with a $235 million oversubscribed PIPE led by Frazier Healthcare and Bain Capital.
The successful merger with Frazier Lifesciences and a substantial PIPE raise enhance liquidity and credibility, signaling strong backing for growth, which can boost investor confidence and stock performance.
Frazier Lifesciences Acquisition Corp. (FLAC) shareholders approved a business combination with NewAmsterdam Pharma, focusing on oral therapies for cardiometabolic diseases.
The approval of the business combination may increase FLAC's market value and enhance investor confidence in NewAmsterdam's potential in the cardiometabolic sector.
Analyst forecasts for Frazier Lifesciences Acquisition Corporation (FLAC) are not currently available. The stock is trading at $17.61.
Analyst ratings for FLAC are not currently available. The stock is currently trading at $17.61. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
Price predictions from Wall Street analysts for FLAC are not currently available. The stock is trading at $17.61.
N/A
Price targets from Wall Street analysts for FLAC are not currently available. The stock is trading at $17.61.
Price targets from Wall Street analysts for FLAC are not currently available. The stock is trading at $17.61.
Analyst ratings for FLAC are not currently available. The stock is trading at $17.61.
Stock price projections, including those for Frazier Lifesciences Acquisition Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.